{"id":3811,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/carvedilol-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"carvedilol-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/carvedilol-txt\/","title":{"rendered":"Carvedilol.txt"},"content":{"rendered":"

Carvedilol<\/h1>\n

CLINICAL USE <\/H3>
\nBeta-adrenoceptor blocker with alpha1-blocking action:<\/p>\n
  • Hypertension, angina and heart failure

    DOSE IN NORMAL RENAL FUNCTION <\/H3>\n
  • Hypertension: 12.5\u201350 mg daily in single or divided doses\n
  • Angina: 12.5\u201325 mg twice daily\n
  • Heart failure: 3.125\u201325 mg twice daily (50 mg twice daily if wt>85 kg)

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :406.5<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>98<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <2<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :2<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :6\u201310\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely dialysability. Dose as in normal renal function. Start with low doses and titrate according to response<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function. Start with low doses and titrate according to response
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function. Start with low doses and titrate according to response
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely dialysability. Dose as in normal renal function. Start with low doses and titrate according to response

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect Analgesics: NSAIDs antagonise hypotensive effectAnti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone\n
  • Antibacterials: concentration reduced by rifampicin\n
  • Antidepressants: enhanced hypotensive effect with MAOIs\n
  • Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin\n
  • Antimalarials: increased risk of bradycardia with mefloquine\n
  • Antipsychotics enhanced hypotensive effect with phenothiazines\n
  • Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil\n
  • Ciclosporin: increased trough concentration, reduce dose by 20% in affected patients\n
  • Diuretics: enhanced hypotensive effect Moxisylyte: possible severe postural hypotension\n
  • Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine\n
  • Tropisetron: increased risk of ventricular arrhythmias \u2013 use with caution

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>First pass elimination of 60\u201375% following oral administration
    \n","protected":false},"excerpt":{"rendered":"

    Carvedilol CLINICAL USE Beta-adrenoceptor blocker with alpha1-blocking action: Hypertension, angina<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3811","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3811"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3811\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}